SG10201805392YA - 1,2,4-triazine-6-carboxamide kinase inhibitors - Google Patents
1,2,4-triazine-6-carboxamide kinase inhibitorsInfo
- Publication number
- SG10201805392YA SG10201805392YA SG10201805392YA SG10201805392YA SG10201805392YA SG 10201805392Y A SG10201805392Y A SG 10201805392YA SG 10201805392Y A SG10201805392Y A SG 10201805392YA SG 10201805392Y A SG10201805392Y A SG 10201805392YA SG 10201805392Y A SG10201805392Y A SG 10201805392YA
- Authority
- SG
- Singapore
- Prior art keywords
- triazine
- carboxamide
- kinase inhibitors
- methods
- syk kinase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
- C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
- C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D253/075—Two hetero atoms, in positions 3 and 5
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Abstract
1,2,4-TRIAZINE-6-CARBOXAMIDE KINASE INHIBITORS Provided are triazine compounds for inhibiting of Syk kinase, intermediates used in making such compounds, methods for their preparation, pharmaceutical compositions thereof, methods for inhibiting Syk kinase activity, and methods for treating conditions mediated at least in part by Syk kinase activity. No Figure
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261663499P | 2012-06-22 | 2012-06-22 | |
US13/841,472 US9040530B2 (en) | 2012-06-22 | 2013-03-15 | 1,2,4-triazine-6-carboxamide kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201805392YA true SG10201805392YA (en) | 2018-08-30 |
Family
ID=49769666
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201805392YA SG10201805392YA (en) | 2012-06-22 | 2013-06-14 | 1,2,4-triazine-6-carboxamide kinase inhibitors |
SG11201408232RA SG11201408232RA (en) | 2012-06-22 | 2013-06-14 | 1,2,4-triazine-6-carboxamide kinase inhibitors |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201408232RA SG11201408232RA (en) | 2012-06-22 | 2013-06-14 | 1,2,4-triazine-6-carboxamide kinase inhibitors |
Country Status (12)
Country | Link |
---|---|
US (1) | US9040530B2 (en) |
EP (1) | EP2863748B1 (en) |
JP (1) | JP6281984B2 (en) |
CN (1) | CN104470363A (en) |
AU (1) | AU2013277476B2 (en) |
CA (1) | CA2876945C (en) |
HK (1) | HK1209277A1 (en) |
IL (1) | IL236057B (en) |
IN (1) | IN2014KN02906A (en) |
SG (2) | SG10201805392YA (en) |
WO (1) | WO2013192049A2 (en) |
ZA (1) | ZA201409256B (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2762476A4 (en) * | 2011-09-30 | 2015-03-25 | Taiho Pharmaceutical Co Ltd | 1,2,4-triazine-6-carboxamide derivative |
RU2015116532A (en) | 2012-10-19 | 2016-12-10 | Ф. Хоффманн-Ля Рош Аг | SYK TYROSINKINASE INHIBITORS |
EP4071144A1 (en) | 2012-11-08 | 2022-10-12 | Bristol-Myers Squibb Company | Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn alpha responses |
WO2014109414A1 (en) * | 2013-01-11 | 2014-07-17 | 富士フイルム株式会社 | Nitrogen-containing heterocylic compound or salt thereof |
CN104870437A (en) * | 2013-01-17 | 2015-08-26 | 四川恒康发展有限责任公司 | Triazine compound, pharmaceutical salt, isomer, or hydrate thereof, and pharmaceutical composition thereof |
JP2016113366A (en) * | 2013-03-29 | 2016-06-23 | 大鵬薬品工業株式会社 | 1,2,4-triazine-6-carboxamide derivative with acetamide group |
WO2015084998A1 (en) | 2013-12-05 | 2015-06-11 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
KR20180021740A (en) * | 2015-06-02 | 2018-03-05 | 파마싸이클릭스 엘엘씨 | Inhibitor of bruton tyrosine kinase |
CN109384774B (en) * | 2017-08-11 | 2023-02-17 | 中国科学院上海药物研究所 | Polysubstituted pyrazine/triazine amide compounds and preparation method and application thereof |
JP2022542704A (en) * | 2019-08-01 | 2022-10-06 | インテグラル バイオサイエンシーズ プライベート リミテッド | Heterocyclic compounds and their use as kinase inhibitors |
WO2021170046A1 (en) * | 2020-02-26 | 2021-09-02 | Beigene, Ltd. | Tyk-2 inhibitor |
WO2022032484A1 (en) * | 2020-08-11 | 2022-02-17 | 北京诺诚健华医药科技有限公司 | Pyridazine-3-formamide compound, and preparation method therefor and medical use thereof |
WO2023108536A1 (en) * | 2021-12-16 | 2023-06-22 | Lynk Pharmaceuticals Co. Ltd. | Tyk2 inhibitors and compositions and methods thereof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4622047B2 (en) * | 1999-06-09 | 2011-02-02 | アステラス製薬株式会社 | Novel heterocyclic carboxamide derivatives |
ATE288420T1 (en) * | 1999-06-09 | 2005-02-15 | Yamanouchi Pharma Co Ltd | NOVEL HETEROCYCLIC CARBOXAMIDE DERIVATIVES |
AU5108000A (en) | 1999-06-10 | 2001-01-02 | Yamanouchi Pharmaceutical Co., Ltd. | Novel nitrogen-contaiing heterocyclic derivatives or salts thereof |
US7723336B2 (en) | 2005-09-22 | 2010-05-25 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
KR20170051521A (en) * | 2008-04-16 | 2017-05-11 | 포톨라 파마슈티컬스, 인코포레이티드 | 2,6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinases inhibitors |
EP2762476A4 (en) * | 2011-09-30 | 2015-03-25 | Taiho Pharmaceutical Co Ltd | 1,2,4-triazine-6-carboxamide derivative |
UY34807A (en) * | 2012-05-16 | 2013-12-31 | Novartis Ag | MONOCYCLIC DERIVATIVES OF HETEROARYL CYCLOALKYL-DIAMINE |
-
2013
- 2013-03-15 US US13/841,472 patent/US9040530B2/en active Active
- 2013-06-14 WO PCT/US2013/046006 patent/WO2013192049A2/en unknown
- 2013-06-14 EP EP13807456.2A patent/EP2863748B1/en active Active
- 2013-06-14 CA CA2876945A patent/CA2876945C/en active Active
- 2013-06-14 CN CN201380037312.3A patent/CN104470363A/en active Pending
- 2013-06-14 AU AU2013277476A patent/AU2013277476B2/en not_active Ceased
- 2013-06-14 SG SG10201805392YA patent/SG10201805392YA/en unknown
- 2013-06-14 SG SG11201408232RA patent/SG11201408232RA/en unknown
- 2013-06-14 IN IN2906KON2014 patent/IN2014KN02906A/en unknown
- 2013-06-14 JP JP2015518471A patent/JP6281984B2/en active Active
-
2014
- 2014-12-04 IL IL236057A patent/IL236057B/en active IP Right Grant
- 2014-12-15 ZA ZA2014/09256A patent/ZA201409256B/en unknown
-
2015
- 2015-10-12 HK HK15109945.0A patent/HK1209277A1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CA2876945C (en) | 2021-07-27 |
AU2013277476B2 (en) | 2016-12-15 |
ZA201409256B (en) | 2019-09-25 |
JP6281984B2 (en) | 2018-02-21 |
US9040530B2 (en) | 2015-05-26 |
IL236057B (en) | 2018-08-30 |
EP2863748B1 (en) | 2018-11-07 |
EP2863748A4 (en) | 2015-12-09 |
EP2863748A2 (en) | 2015-04-29 |
HK1209277A1 (en) | 2016-04-01 |
WO2013192049A3 (en) | 2014-02-13 |
AU2013277476A1 (en) | 2015-01-22 |
CN104470363A (en) | 2015-03-25 |
IN2014KN02906A (en) | 2015-05-08 |
US20130345191A1 (en) | 2013-12-26 |
JP2015520232A (en) | 2015-07-16 |
SG11201408232RA (en) | 2015-01-29 |
WO2013192049A2 (en) | 2013-12-27 |
IL236057A0 (en) | 2015-02-01 |
CA2876945A1 (en) | 2013-12-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG10201805392YA (en) | 1,2,4-triazine-6-carboxamide kinase inhibitors | |
PH12020500195A1 (en) | Pyrimidinones as factor xia inhibitors | |
PH12021550418A1 (en) | Macrocycles with hetrocyclic p2` groups as factor xia inhibitors | |
PH12017502141A1 (en) | Compounds and their methods of use | |
MX363551B (en) | Pyrazine kinase inhibitors. | |
TN2013000348A1 (en) | Compounds and compositions as trk inhibitors | |
PH12014501365A1 (en) | Compounds | |
MX2013009873A (en) | Tricyclic inhibitors of kinases. | |
MX2015000892A (en) | Dihydropyridone p1 as factor xia inhibitors. | |
TN2014000138A1 (en) | Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases. | |
EA027213B9 (en) | Pyrazolopyrimidine compounds as kinase inhibitors | |
MX2013012776A (en) | Amino-pyridine-containing spleen tyrosine kinase (syk) inhibitors. | |
MD4820B1 (en) | Substituted dihydroisoquinolinone compounds | |
PH12014501829A1 (en) | Bicyclic pyrazinone derivatives | |
MX2014013090A (en) | Pyrrolotriazinone derivatives. | |
WO2014058921A3 (en) | Substituted pyrimidinyl kinase inhibitors | |
WO2014051654A3 (en) | Bicyclic oxa-lactam kinase inhibitors | |
WO2013192046A3 (en) | Substituted picolinamide kinase inhibitors |